Atlas Venture Life Science Advisors, LLC Q4 2022 Filing

Filed February 14, 2023

Portfolio Value

$830.2B

Holdings

17

Report Date

Q4 2022

Filing Type

13F-HR

All Holdings (17 positions)

#StockSharesValue% PortfolioType
1
DAWNDay One Biopharmaceuticals, Inc.
7,568,317$162.9B19.62%
2
KYMRKymera Therapeutics, Inc.
5,984,736$149.4B17.99%
3
DYNDyne Therapeutics, Inc.
9,869,483$114.4B13.78%
4
VIGLVigil Neuroscience, Inc.
5,836,874$73.0B8.79%
5
IRONDisc Medicine, Inc.
3,461,784$68.9B8.29%
6
AVTEAerovate Therapeutics, Inc.
2,017,521$59.1B7.12%
7
REPLReplimune Group, Inc.
2,098,300$57.1B6.87%
8
THRDThird Harmonic Bio, Inc.
10,907,859$46.9B5.65%
9
AKROAkero Therapeutics, Inc.
594,251$32.6B3.92%
10
GBIOGBXGeneration Bio, Co.
8,278,876$32.5B3.92%
11
Ikena Oncology, Inc.
5,018,178$13.3B1.61%
12
XLOXilio Therapeutics, Inc.
2,759,344$7.4B0.89%
13
F-star Therapeutics, Inc.
599,524$3.8B0.46%
14
AVROBIO INC
4,520,863$3.2B0.39%
15
VRDNViridian Therapeutics, Inc.
90,072$2.6B0.32%
16
SPROSPERO THERAPEUTICS INC
1,031,160$1.8B0.21%
17
MAGENTA THERAPEUTICS INC
3,476,536$1.4B0.17%